Panangin tablets p / o, No. 50

Panangin tablets p / o, No. 50; 'To eliminate the deficiency of potassium and magnesium as part of combination therapy for: - various manifestations of coronary heart disease (including acute myocardial infarction); - chronic heart failure; - heart rhythm disturbances (including arrhythmias caused by an overdose of cardiac glycosides)

Before using it is necessary to consult a doctor.
Inside, the drug should be used after meals. the acidic environment of the stomach reduces its effectiveness.
The usual daily dose: 1-2 tablets. 3 times a day. Maximum daily dose: 3 tablets 3 times a day.
The duration of the drug intake and the need for repeated courses are determined by the doctor.

Active ingredients:
Magnesium asparaginate 140.0 mg
(in the form of magnesium asparaginate Х 4 H2O - 175.00 mg) and potassium asparaginate 158.0 mg
(in the form of potassium asparaginate Х 1/2 H2O - 166.30 mg).
Excipients:
Silicon dioxide, colloidal - 2.00 mg, povidone K30 - 3.30 mg, magnesium stearate - 4.00 mg, talc - 10.00 mg, corn starch - 86.10 mg, potato starch - 3.30 mg in the core of the tablets.
Shell composition:
Macrogol 6000 - 1.40 mg, titanium dioxide Tsv. ind. 77891, E171 - 5.30 mg, butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate copolymer [1: 2: 1] - 6.00 mg, talc - 7.30 mg.

Hypersensitivity to any of the constituent components of the drug, acute and chronic renal failure, hyperkalemia, hypermagnesemia, Addison's disease, I-III degree atrioventricular block, cardiogenic shock (blood pressure less than 90 mm Hg), impaired amino acid metabolism, severe myasthenia gravis , hemolysis, acute metabolic acidosis, dehydration.

Carefully

Pregnancy (especially in the first trimester) and during lactation.

Trade name : PananginЃ

Dosage form : film-coated tablets.

Composition:

Active ingredients:
Magnesium asparaginate 140.0 mg
(in the form of magnesium asparaginate Х 4 H2O - 175.00 mg)

Potassium asparaginate 158.0 mg
(in the form of potassium asparaginate Х 1/2 H2O - 166.30 mg).
Excipients:
Silicon dioxide, colloidal - 2.00 mg, povidone K30 - 3.30 mg, magnesium stearate - 4.00 mg, talc - 10.00 mg, corn starch - 86.10 mg, potato starch - 3.30 mg in the core of the tablets.
Shell composition:
Macrogol 6000 - 1.40 mg, titanium dioxide Tsv. ind. 77891, E171 - 5.30 mg, butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate copolymer [1: 2: 1] - 6.00 mg, talc - 7.30 mg.

Description

Round biconvex film-coated tablets, white or almost white, with a slightly shiny and uneven surface, almost odorless.

Pharmacological group : potassium and magnesium drug.

Pharmacological properties

Pharmacodynamics : the most important intracellular cations K + and Mg ++ play a key role in the functioning of numerous enzymes, in the formation of bonds between macromolecules and intracellular structures, and in the mechanism of muscle contractility. The intra- and extracellular ratio of potassium, calcium, sodium and magnesium ions affects myocardial contractility. Endogenous aspartate acts as a conductor of ions: it has a high affinity for cells, due to the slight dissociation of its salts, ions in the form of complex compounds penetrate into the cell. Magnesium and potassium aspartates improve myocardial metabolism. Lack of magnesium / potassium predisposes to the development of hypertension, atherosclerosis of the coronary arteries, arrhythmias and metabolic changes in the myocardium.
Pharmacokinetics: Absorption is high. It is excreted by the kidneys.

Indications for use

As an additional agent in the treatment of chronic heart diseases (heart failure, condition after myocardial infarction), cardiac arrhythmias (primarily ventricular arrhythmias), in the treatment of digitalis; replacement therapy for a lack of magnesium / potassium in food.

Contraindications

Hypersensitivity to any of the constituent components of the drug, acute and chronic renal failure, hyperkalemia, hypermagnesemia, Addison's disease, I-III degree atrioventricular block, cardiogenic shock (blood pressure less than 90 mm Hg), impaired amino acid metabolism, severe myasthenia gravis , hemolysis, acute metabolic acidosis, dehydration.

Carefully

Pregnancy (especially in the first trimester) and during lactation.

Method of administration and dosage

Before using it is necessary to consult a doctor.
Inside, the drug should be used after meals. the acidic environment of the stomach reduces its effectiveness.
The usual daily dose: 1-2 tablets. 3 times a day. Maximum daily dose: 3 tablets 3 times a day.
The duration of the drug intake and the need for repeated courses are determined by the doctor.

Side effect

Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the pancreas (in patients with anacid gastritis or cholecystitis), atrioventricular block, paradoxical reaction (an increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, paresthesia) (reddening of the face, feeling of thirst, lowering blood pressure, hyporeflexia, respiratory depression, convulsions).

Overdose

Symptoms: impaired conduction (especially with previous pathology of the cardiac conduction system).
Treatment: intravenous administration of calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

Interaction with other medicinal products

Pharmacodynamic: combined use with potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and asystole. The use of potassium preparations in conjunction with glucocorticosteroids eliminates the hypokalemia caused by the latter. Under the influence of potassium, the undesirable effects of cardiac glycosides are reduced. Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs. Magnesium reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. Anesthetics increase the inhibitory effect of magnesium preparations on the central nervous system; with simultaneous use with atracuronium, decametonium,with succinyl chloride and suxamethonium, an increase in neuromuscular blockade is possible; calcitriol increases the content of magnesium in the blood plasma, calcium preparations reduce the effect of magnesium preparations.
Pharmacokinetic : astringent and coating agents reduce the absorption of the drug in the gastrointestinal tract and it is necessary to observe the three-hour interval between taking PananginЃ inside with the listed agents.

special instructions

Patients with diseases accompanied by hyperkalemia require special attention: regular monitoring of the ionogram is required.

Impact on the ability to drive and perform work associated with an increased risk of injury : does not affect the ability to drive and engage in activities that require increased concentration of attention and speed of psychomotor reactions.

Release form

Film-coated tablets.
50 tablets in a polypropylene bottle. 1 bottle in a cardboard box with instructions for use.

Storage conditions

At a temperature of 15-30 ? C. Keep out of the reach of children.

Shelf life

5 years.
Do not use the drug after the expiration date.

Conditions of dispensing from pharmacies

Without recipe.